Acceleron uncorks more mid-stage data for PAH drug sotatercept as part of the drug's resurrection campaign

Once on life support in pulmonary arterial hypertension, Acclereron’s sotatercept came back from the brink with winning data early last year. Now, with Phase III pivotal studies on the way, Acceleron is adding more data to its scrapbook in preparation for an eventual sit-down with regulators.